Introduction {#s1}
============

Age is the greatest risk factor for Alzheimer\'s disease (AD) and related dementias. While genetic risk factors have been the major focus of AD drug discovery, it is important to consider the progressively detrimental metabolic processes that take place with normal aging as possible therapeutic targets. Clinical evidence shows that a decline in cerebral glucose metabolism (hypometabolism) precedes the pathology and symptoms of AD and is more severe than that observed in normal aging ([@bib9]; [@bib10]; [@bib47]). Given that energy production from glucose supports the majority of brain activity as well as the maintenance of cellular homeostasis, it is likely that a failure to supply cells with adequate energy contributes to the neuropathological cascade in both aging and age-associated dementias such as AD ([@bib3]).

Most of the energy derived from glucose oxidation is produced in mitochondria. Not surprisingly, a number of mitochondrial-dependent functions are found to be impaired during aging and AD ([@bib3]; [@bib4]; [@bib12]; [@bib28]; [@bib34]; [@bib43]; [@bib48]). In fact, brain mitochondrial dysfunction has been hypothesized to be responsible for the pathological hallmarks of AD ([@bib43]; [@bib48]).

Because the current approach to AD drug discovery has largely failed, we devised a novel drug discovery paradigm based on phenotypic screening assays that mimic numerous aspects of old age-associated neurodegeneration and brain pathology, including energy failure and mitochondrial dysfunction ([@bib37]). We have identified two compounds that are very neuroprotective -- CMS121 and J147. J147 is active in transgenic AD animal models ([@bib5]; [@bib16]; [@bib36]; [@bib38]). It enhances memory and prevents some aspects of aging in rapidly aging (15 month median lifespan) senescence-accelerated prone 8 (SAMP8) mice when administered early in life ([@bib13]). CMS121 is a more potent derivative of the flavonol fisetin that maintains most of its biological properties ([@bib8]). CMS121 is not as well studied as J147, but we have recently shown that fisetin is able to ameliorate some aspects of aging in SAMP8 mice ([@bib14]). The target of J147 is the alpha subunit of ATP synthase, which engages a neuroprotective response involving the activation of AMP-activated protein kinase (AMPK) ([@bib21]). ATP synthase is an anti-aging target in *C. elegans* ([@bib7]). We have ruled out that CMS121 also targets ATP synthase (unpublished data), and its molecular targets are currently under investigation. However, because the two compounds were developed based upon brain toxicities associated with aging and therefore share similar biological activities in vitro, we hypothesized that they may mitigate some aspects of aging brain metabolism and pathology via a common pathway despite differences in molecular structure and direct targets.

To test this idea, we fed CMS121 and J147 to aged SAMP8 mice and used a multiomics approach to identify modes of action. We first show that both compounds reduce metabolic and gene transcription markers of aging in the SAMP8 model of aging and dementia when administered at a late stage of the aging process. We further demonstrate that both compounds share a mechanism of action that maintains high levels of acetyl-coenzyme A (acetyl-CoA), at least in part, by the inhibition of acetyl-CoA carboxylase 1 (ACC1). Importantly, the compounds increase histone acetylation in cultured neurons and SAMP8 mice at a site on histone H3 that is required for memory formation ([@bib31]). Together, these data show that aging and dementia share a common metabolic pathway related to brain mitochondrial function that can be therapeutically targeted.

Results {#s2}
=======

Aging is associated with changes in the hippocampal transcriptome that are prevented by CMS121 and J147 {#s2-1}
-------------------------------------------------------------------------------------------------------

To identify age-dependent changes in brain metabolism that are causally associated with dementia, we tested CMS121 and J147 in SAMP8 mice. The SAMP8 mice are a model of accelerated aging that develop a progressive, age-associated decline in brain function as well as a number of brain pathologies similar to human dementia and AD patients ([@bib1]; [@bib2]; [@bib13]; [@bib32]; [@bib35]; [@bib44]). Some of the pathological traits developed by the SAMP8 mice with aging that are also found in AD include: progressive decline in brain function with early deterioration in learning and memory; increased oxidative stress; inflammation; vascular impairment; gliosis; Aβ accumulation and tau hyperphosphorylation ([@bib6]; [@bib32]; [@bib44]).

We asked whether J147 and CMS121 could prevent the development of the aging phenotype in SAMP8 mice when administered in the last quadrant of their lifespan, reflecting the therapeutic context for human AD patients. Treatment with the diets containing the compounds started at 9 months of age and continued for four months (13 months of age); the median lifespan of these mice is 15 months.

We began our analyses with an unbiased approach by studying the entire transcriptome of brain hippocampal tissue. Principle component analysis (PCA) showed a clear distinction in the variation of the transcriptome between the 9 and 13 months old SAMP8 groups, indicating that aging has a strong effect on gene expression ([Figure 1A](#fig1){ref-type="fig"}). Importantly, both compound-treated groups presented a distribution in the two major principle components (PCs) that was closer to the 9 months old mice, suggesting that the compounds can prevent transcriptomic changes that take place with aging ([Figure 1A](#fig1){ref-type="fig"}). This effect was particularly noticeable with CMS121. Transcriptomic drift analysis, a method to characterize the aging process that measures changes in gene expression at a global level ([@bib39]), showed a significant age-associated drift in gene expression between 9 and 13 months that was also suppressed by both compounds ([Figure 1B](#fig1){ref-type="fig"}).

![Aging of the hippocampal transcriptome in SAMP8 mice is significantly prevented by CMS121 and J147.\
(**A**) PCA of the top 10% most highly expressed genes in the hippocampus of 9 months, 13 months, 13 months+CMS121 and 13 months+J147 SAMP8 mice. Cutoff was sum(log2(FPKM+5))\>=110.41 (2458 genes selected; n = 5--6/group). Ellipses show the 70% confidence interval. (**B**) Drift analysis of the whole transcriptome. Values are expressed as box-and-whisker plots. Brown-Forsythe test. n = 5--6/group. (**C**) Venn diagrams illustrating shared and uniquely affected genes between the 9 months vs 13 months old mice and 13 months vs each of the 13 months+compounds. n = 5--6/group. Please see Supplemental Materials and methods for detailed statistical analysis. Correlation of gene expression for each group of genes is represented on the right side of the panel (units are -log(fold change)).](elife-47866-fig1){#fig1}

To support the PCA and drift analysis, we examined the effects of the compounds on the expression of individual genes. 485 differently expressed (DE) genes were found between the 9 and 13 months old SAMP8 mice ([Figure 1C](#fig1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"}). 684 and 34 DE genes were detected between the 13 months and 13 months+CMS121 and 13 months+J147 SAMP8 mice, respectively ([Figure 1C](#fig1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"}). Venn diagrams highlighting the shared DE genes between the 9 months vs 13 months old mice and 13 months vs each of the 13 months+compounds are shown in [Figure 1C](#fig1){ref-type="fig"}. Fold changes of the DE genes were log-transformed and plotted on correlation graphs for each pair of comparisons ([Figure 1C](#fig1){ref-type="fig"}, right side). For all of the DE genes that overlap between aging and compound treatment (shared DE genes), the age-dependent changes in expression were prevented by the compounds ([Figure 1C](#fig1){ref-type="fig"}, middle set of graphs). Furthermore, analysis of the DE genes that are specific for each comparison (those that do not overlap) also shows that the age-dependent alterations in most of these DE genes follow the same trend of prevention by the compounds. Thus, these data provide evidence that both compounds reduce aging at the level of the transcriptome in the hippocampus of SAMP8 mice when administered at a late stage of the aging process.

CMS121 and J147 improve cognitive function in SAMP8 mice when administered at advanced stages of dementia {#s2-2}
---------------------------------------------------------------------------------------------------------

We next determined if the changes in gene transcription in old SAMP8 mice and the effects by CMS121 and J147 were associated with functional alterations in cognition.

Assessment of spontaneous behavior in the open field assay showed only a decline in average velocity between the 9 and 13 months SAMP8 mice ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The compounds had no effect on this parameter or on body weights ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). To investigate the effects of CMS121 and J147 on age-associated cognitive decline, mice were tested using the elevated plus maze ([Figure 2A](#fig2){ref-type="fig"}) and the Barnes maze ([Figure 2B](#fig2){ref-type="fig"}).

![CMS121 and J147 preserve cognitive parameters in SAMP8 mice when administered at advanced stages of the phenotype.\
(**A**) The elevated plus maze was used to measure disinhibition behavior in 9 months, 13 months, 13 months+CMS121 and 13 months+J147 SAMP8 mice. One-way ANOVA followed by Tukey-Kramer post-hoc test (n = 11--18/group). (**B**) Spatial learning/memory was evaluated in the same mice by the Barnes maze assay. All data are mean ± SD. Two-way repeated measures ANOVA and post hoc Bonferroni corrected t-test (n = 5--9/group).](elife-47866-fig2){#fig2}

The elevated plus maze examines disinhibition behavior based on the aversion of normal mice to open spaces. Dementia is clinically associated with disinhibition and AD mouse models tend to exhibit increased disinhibition ([@bib13]; [@bib36]). 13 months old SAMP8 mice spent significantly more time in the open arms compared to 9 months old SAMP8 mice ([Figure 2A](#fig2){ref-type="fig"}). The age-associated increase in disinhibition was prevented by CMS121 and J147.

The Barnes maze is used to analyze spatial learning and hippocampal-dependent memory. In this assay, mice use visual cues to locate a hidden box. No changes between the groups were found in the escape latencies during the learning and the retention phases (data not shown). However, when tested during the reversal phase, which is more sensitive to deficits in memory and learning, CMS121 significantly improved the learning of the new location ([Figure 2B](#fig2){ref-type="fig"}). J147 had no significant effect. These data show that the transcriptomic aging in old SAMP8 mice is associated with a decline in cognitive function and that J147 and CMS121 prevent some of this deterioration.

Suppression of transcriptomic aging by the compounds is specifically associated with the maintenance of brain mitochondria-related genes {#s2-3}
----------------------------------------------------------------------------------------------------------------------------------------

We next asked whether there were specific cellular processes that were targeted by the compounds that could explain their beneficial effects. To address this, we carried out pathway analysis with the 485 DE genes that were altered with aging ([Figure 3A](#fig3){ref-type="fig"}) and with the 684 DE genes that were altered by CMS121 ([Figure 3B](#fig3){ref-type="fig"}). Given the small number of 34 DE genes detected with J147, this comparison was left out from the pathway analysis. However, the effects of J147 were included in the subsequent analyses.

![CMS121 and J147 specifically maintain the expression of genes associated with the mitochondria that are altered with aging in SAMP8 mice.\
Top KEGG pathways and respective enrichment scores associated with the 485 genes with altered expression in 9 months vs 13 months SAMP8 mice (**A**) and with the 684 genes with altered expression in 13 months vs 13 months+CAD121 (**B**) SAMP8 mice. Gene overlap for the KEGG pathways oxidative phosphorylation (OP), Parkinson\'s disease (PD), Huntington\'s disease (HD) and Alzheimer\'s disease (AD) in 13 months vs 13 months+CMS121 SAMP8 mice is shown. n = 5--6/group. (**C**) Heatmap of the fold gene expression for 9 months/13 months, 13 months/13 months+CMS121 and 13 months/13 months+J147, regarding the mitochondrial genes present in the pathways OP, PD, HD and AD. The log2 fold-change (FC) is plotted in red--blue color scale with red indicating up-regulation and blue indicating down-regulation. ETC: Electron transport chain complex; CI = Complex I; CIII = Complex III; CIV = Complex IV; CV = Complex V. (**D**) Heatmap of the fold gene expression for 9 months/13 months, 13 months/13 months+CMS121 and 13 months/13 months+J147, regarding all genes from the mitochondrial DNA with detectable expression levels. Color key = log2 FC. (**E**) Cluster two from the clustering heatmap (K-means, Euclidean distance on normalized log2(FPKM+5) for 20077 genes) of the whole hippocampal transcriptome of 9 months, 13 months, 13 months+CMS121 and 13 months+J147 SAMP8 mice (For full heatmap see [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). (**F**) Top KEGG pathways associated with cluster 2. (**G**) Transcriptomic drift of genes that encode for all proteins known to be associated with the mitochondria (Mitocarta). Values are expressed as box-and-whisker plots. Brown-Forsythe test. n = 5--6/group. (**H**) Mitochondrial DNA copy number in the hippocampus (normalized to 9 months). Data are mean ± SD. One-way ANOVA followed by Tukey-Kramer post-hoc test (n = 5/group).](elife-47866-fig3){#fig3}

CMS121 affected a number of different pathways ([Figure 3B](#fig3){ref-type="fig"}), some of which were also modified with aging ([Figure 3A](#fig3){ref-type="fig"}). The top KEGG pathway targeted by both aging and CMS121 was oxidative phosphorylation (OP). Moreover, the majority of the DE genes in this pathway are the same for both aging and CMS121 (overlap p-value\<0.01, Fisher's Exact Test). In addition, the set of DE genes in the OP pathway largely overlapped with those from the Parkinson\'s disease (PD), AD and Huntington\'s disease (HD) pathways ([Figure 3B](#fig3){ref-type="fig"}). These genes included nuclear genes that encode for subunits of complexes I, III and IV of the electron transport chain (ETC) and ATP synthase (complex V) in the mitochondria ([Figure 3C](#fig3){ref-type="fig"}). Surprisingly, the expression of all these genes went up between 9 and 13 months in the SAMP8 mice and this was prevented by CMS121 and J147 ([Figure 3C](#fig3){ref-type="fig"}). We also observed the same effect with genes encoded by the mitochondrial DNA, which code for proteins necessary for oxidative phosphorylation as well as the tRNA and rRNA necessary for translation in the mitochondria ([Figure 3D](#fig3){ref-type="fig"}).

A similar conclusion was reached when we used an alternative approach by clustering the whole transcriptome according to gene expression patterns. We found one large cluster (cluster 2) that showed increased changes in gene expression with aging that were prevented by the compounds ([Figure 3E,F](#fig3){ref-type="fig"}), and whose top KEGG pathways were the same as the ones identified in [Figure 3A and B](#fig3){ref-type="fig"}, including oxidative phosphorylation, Parkinson\'s disease, Huntington\'s disease and Alzheimer\'s disease. Finally, the transcriptomic drift analysis of the Mitocarta genes shows that both compounds are effective in preventing the drift of transcripts associated with mitochondrial proteins ([Figure 3G](#fig3){ref-type="fig"}).

The analysis of all genes that encode proteins associated with the mitochondria shows both up- and down-regulated changes in expression during aging ([Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). In order to understand whether the changes in ETC gene expression were related to alterations in the number of mitochondria, we measured mitochondrial DNA copy number. We found that mitochondrial DNA copy number went down with age in SAMP8 mice and that only J147 was able to significantly prevent that decrease ([Figure 3H](#fig3){ref-type="fig"}). These data show that changes in mitochondrial gene expression correlate with the aging SAMP8 phenotype and are partly prevented by CMS121 and J147.

CMS121 and J147 preserve key brain mitochondrial metabolites that are altered during aging {#s2-4}
------------------------------------------------------------------------------------------

We next tested the hypothesis that the coordinated responses at the gene expression level with aging are associated with dysregulation at the metabolic level. To do this, we carried out large-scale, untargeted metabolic profiling of brain cortical tissue from 9 months, 13 months and 13 months+compound-treated SAMP8 mice. This study not only assessed the levels of metabolites that directly participate in brain mitochondrial metabolic pathways, such as the tricarboxylic acid (TCA) cycle and fatty acid synthesis/oxidation, but also metabolites that are involved in many other pathways. A total of 496 small molecules were measured. 205 metabolites were significantly altered between 9 and 13 months in the SAMP8 mice and the alterations in some of these metabolites were prevented by CMS121 and J147 ([Figure 4C](#fig4){ref-type="fig"}). Global suppression of age-related metabolomic changes by the compounds was not as robust as with the transcriptome. This observation was confirmed by the PCA and metabolic drift analyses ([Figure 4A,B](#fig4){ref-type="fig"}).

![Global metabolic analysis of brain cortex and blood plasma.\
PCA of the 496 and 604 metabolites measured in the brain cortex (**A**) and blood plasma (**D**), respectively, of 9 months, 13 months, 13 months+CMS121 and 13 months+J147 SAMP8 mice. (n = 6/group). Drift analysis of cortex (**B**) and plasma (**E**) metabolites. Values are expressed as box-and-whisker plots. Brown-Forsythe test. n = 6/group. Venn diagrams illustrating shared and uniquely affected cortex (**C**) and plasma (**F**) metabolites between the 9 months vs 13 months old mice and 13 months vs each of the 13 months+compounds. n = 6/group. Correlation of metabolite levels for each group of genes is represented on the right side of the panel (units are -log(fold change)).](elife-47866-fig4){#fig4}

We also measured the levels of metabolites in the plasma of the same animals. Both compounds showed a partial suppression of the changes that took place with aging ([Figure 4E,F](#fig4){ref-type="fig"} and [Supplementary file 3](#supp3){ref-type="supplementary-material"}). Although not as clear in the PCA ([Figure 4D](#fig4){ref-type="fig"}), the metabolic drift analysis showed a significant suppression of plasma metabolic drift by CMS121 and J147 ([Figure 4E](#fig4){ref-type="fig"}). This is also evident in the correlation graphs for the metabolites in common between the comparisons of 9 months Vs 13 months and 13 months Vs 13 months+compounds ([Figure 4F](#fig4){ref-type="fig"}).

A detailed investigation of individual metabolites measured in the brain that participate in the TCA cycle revealed profound changes with aging that were partially prevented by both CMS121 and J147 ([Figure 5A](#fig5){ref-type="fig"}). In fact, increases of 9.51, 7.85, 6.19 and 5.73-fold between 9 and 13 months old SAMP8 mice in the levels of α-ketoglutarate, succinate, citrate and aconitate, respectively, accounted for the top largest fold changes seen with aging, while there was a 2-fold decrease in acetyl-CoA ([Figure 5A](#fig5){ref-type="fig"} and [Supplementary file 2](#supp2){ref-type="supplementary-material"}). CMS121 had the largest effect on the metabolites, significantly restoring the levels of acetyl-CoA, α-ketoglutarate and succinate to 9 months old levels ([Figure 5A](#fig5){ref-type="fig"}). J147 also preserved the levels of acetyl-CoA and, although not statistically significant, it reduced the increases in α-ketoglutarate and succinate seen with aging ([Figure 5A](#fig5){ref-type="fig"}).

![CMS121 and J147 modulate key metabolites associated with mitochondria in the brain of SAMP8 mice.\
(**A**) Levels of TCA metabolites detected in the cortex of 9 months, 13 months, 13 months+CMS121 and 13 months+J147 SAMP8 mice. Values are expressed as box-and-whisker plots. One-way ANOVA followed by Tukey-Kramer post-hoc test (n = 6/group). Pathway enrichment analysis with cortex metabolites found altered in 9 months vs 13 months (**B**), 13 months vs 13 months+CMS121 (**C**), and 13 months vs 13 months+J147 (**D**). Enrichment scores were calculated as described in the Supplemental Materials and methods. Number of metabolites altered in a biological pathway and the total number of metabolites measured in that pathway (Altered/detected) are shown as a complement to the enrichment score. (**E**) Levels of all acyl carnitine metabolites measured in the cortex of 9 months, 13 months, 13 months+CMS121 and 13 months+J147 SAMP8 mice. Values are expressed as box-and-whisker plots. One-way ANOVA followed by Tukey-Kramer post-hoc test (n = 6/group).](elife-47866-fig5){#fig5}

Pathway enrichment analysis with all of the brain metabolites that were significantly altered with aging confirmed that the TCA cycle was among the top pathways preferentially affected ([Figure 5B](#fig5){ref-type="fig"}). In addition, a number of pathways that either interact with or directly take place in the mitochondria were also detected (in red), including oxidative phosphorylation, urea cycle, glutamate metabolism, pantothenate/CoA and glycolysis ([Figure 5B](#fig5){ref-type="fig"}).

We then carried out pathway enrichment analysis with the brain metabolites that were altered by the compounds in relation to the 13 months old mice and found that both compounds shared a common top pathway related to the metabolism of acyl carnitines ([Figure 5C and D](#fig5){ref-type="fig"}). The levels of the different acyl carnitines did not significantly change between 9 and 13 months, but many were increased by CMS121 and J147 in the old animals ([Figure 5E](#fig5){ref-type="fig"}), suggesting a shared mechanism of action for the compounds. Acyl carnitines are intermediary metabolites of fatty acid β-oxidation involved in the transport of the acyl moiety into the mitochondria where it is oxidized to produce acetyl-CoA. The levels of carnitine, which is necessary for the transport of the acyl groups across the mitochondrial inner membrane, were also significantly decreased in 13 months old mice and rescued by the compounds ([Figure 5E](#fig5){ref-type="fig"}).

Although no pathway analysis with the metabolic data from the plasma was pursued due to the heterogeneous nature of plasma metabolites derived from diverse tissues and organs, the data demonstrate that the compounds also had a systemic effect on some parameters of aging.

Specifically, these data show that the maintenance of mitochondrial gene expression in the brain by CMS121 and J147 is associated with a preservation of key mitochondrial metabolic intermediates. Moreover, the build-up in acyl carnitines with both compounds is suggestive of a mitochondrial target underlying the action of the compounds.

CMS121 and J147 enhance acetyl-CoA levels and histone acetylation in neurons {#s2-5}
----------------------------------------------------------------------------

To further delineate the overall changes in metabolism shared by both compounds, network analysis was carried out by GAM integrating both the transcriptomic and the metabolomic data. Analysis of the networks generated for each compound showed that acetyl-CoA is a central metabolite shared by CMS121 and J147 ([Figure 5---figure supplement 1A,B](#fig5s1){ref-type="fig"}). To rule out the possibility of capturing acetyl-CoA in the network just by chance, random sampling of the transcriptomic and the metabolomics data was performed followed by network analysis, and confirmed the central role of acetyl-CoA in the experiments (random sampling p=0.01). Importantly, the decrease in the levels of acetyl-CoA in the brains of 13 months old SAMP8 mice was prevented by CMS121 and J147 ([Figure 5A](#fig5){ref-type="fig"}).

To provide further support for the central role of acetyl-CoA in the effects of the compounds, network analysis was performed on transcriptomic data from cultured, differentiated rat cortical neurons treated with CMS121 and J147. This analysis also identified acetyl-CoA as a central metabolite regulated by both compounds ([Figure 5---figure supplement 1C,D](#fig5s1){ref-type="fig"}; random sampling, p=0.01). Measurement of acetyl-CoA in these cells confirmed that both compounds induced a significant increase ([Figure 6A](#fig6){ref-type="fig"}).

![CMS121 and J147 increase acetyl-CoA levels associated with inhibition of ACC1.\
Increases in acetyl-CoA levels are protective and associated with inhibition of ACC1 by CMS121 and J147. (**A**) Total levels of acetyl-CoA in rat primary neurons (n = 5/group), after treatment with 1 μM of each compound for 24 hr. Acetylation of H3 at Lys 9 (Ac-H3K9) was assessed by Western blotting and normalized to levels of total H3 in rat primary neurons (n = 3/group) (**B**) and mouse cortical tissue (n = 5/group) (**C**). (**D**) Protection during oxytosis in HT22 cells with CMS121 (500 nM) and J147 (50 nM) (n = 3/group). (**E**) Total levels of acetyl-CoA in HT22 cells (n = 3/group). Phosphorylation of ACC1 was assessed by Western blotting and normalized to levels of respective total protein in rat primary neurons (n = 3/group) (**F**), HT22 cells (n = 3/group) (**G**) and SAMP8 mouse cortical tissue (n = 5/group) (**H**). Scans of the blots are shown in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}. (**I**) Fold change in the levels of different polyunsaturated fatty acids in primary neurons treated with 1 μM of each compound for 24 hr. Fold change in the levels of multiple long-chain fatty acids including major polyunsaturated fatty acids in the brains (**J**) and plasma (**K**) of old SAMP8 treated with CMS121 and J147, relative to old SAMP8. (**L**) Total levels of acetyl-CoA in HT22 cells treated with 5 mM glutamate alone or in the presence of 3, 10 or 30 μM TOFA, determined 8 hr after treatment (n = 3/group). (**M**) Protection during oxytosis in HT22 cells after inhibition of ACC1 with 3, 10 or 30 μM TOFA (n = 3/group). (**N**) Total levels of acetyl-CoA in HT22 cells after knock down with ACC1 siRNA, measured 48 hr after knock down (n = 3/group). Protection during oxytosis (**O**) and ferroptosis (**P**) in HT22 cells after knock down with ACC1 siRNA (n = 3/group). (**Q**) Protection during ferroptosis in HT22 cells with CMS121 (250 nM) and J147 (100 nM) (n = 3/group). (**R**) Protection during oxytosis in HT22 cells treated with sodium acetate (Ac), with survival normalized to control treatment with sodium chloride. All data are mean ± SD. One-way ANOVA followed by Tukey-Kramer post-hoc test.](elife-47866-fig6){#fig6}

Acetyl-CoA is used by histone acetyltransferases to acetylate histones and thereby regulate memory by restructuring chromatin in the brain ([@bib31]). In primary cortical neurons, CMS121 and J147 significantly increased acetylation of histone 3 at lysine 9 (H3K9) ([Figure 6B](#fig6){ref-type="fig"}), an epitope that has been implicated in memory formation ([@bib20]; [@bib31]). Importantly, acetylation of H3K9 was reduced in the cortex of 13 months old SAMP8 mice relative to 9 months old mice and both CMS121 and J147 significantly prevented this loss ([Figure 6C](#fig6){ref-type="fig"}). We obtained similar results in the APPswe/PSEN1dE9 transgenic mouse model of AD in which old symptomatic mice were fed CMS121 and J147 that resulted in improved cognition and reduced pathology ([@bib36] and data submitted for publication). In both cases, acetylation of H3K9 was increased by the compounds ([Figure 6---figure supplement 1D--G](#fig6s1){ref-type="fig"}). These data identify acetyl-CoA as a central metabolite that is decreased in the aging brain and increased by CMS121 and J147, and this increase is associated with acetylation of histone H3 at a site required for memory enhancement.

Increases in acetyl-CoA levels are neuroprotective and are associated with inhibition of ACC1 by CMS121 and J147 {#s2-6}
----------------------------------------------------------------------------------------------------------------

We have recently demonstrated that the mechanism of action of J147 is associated with the activation of AMPK ([@bib21]). One of the downstream effects of AMPK activation is the inhibition by phosphorylation at serine 79 of acetyl-CoA carboxylase 1 (ACC1), an enzyme responsible for the conversion of acetyl-CoA into malonyl-CoA, which is then utilized to synthesize fatty acids. The flux of acetyl-CoA through ACC1 to malonyl-CoA is a major mechanism of acetyl-CoA catabolism and lipid biosynthesis. Inhibition of ACC1 can thus potentially lead to a build up in acetyl-CoA. Therefore, we determined the effects of the compounds on ACC1 phosphorylation and acetyl CoA levels in both primary neurons and the mouse hippocampal neuronal cell line HT22, the primary phenotypic screening model used in our laboratory to identify CMS121 and J147 ([@bib5]; [@bib8]) ([Figure 6D](#fig6){ref-type="fig"}). This assay relies on the lethal induction of mitochondrial ROS in the HT22 cells ([@bib37]), a programmed cell death pathway called oxytosis with physiological features similar to those implicated in the nerve cell damage seen in aging and AD ([@bib15]; [@bib45]). Oxytosis can be triggered by glutamate which inhibits cystine uptake via system X~c~^-^, leading to depletion of intracellular glutathione (GSH), production of ROS and cell death ([@bib45]).

We first determined that the compounds can increase acetyl-CoA in these cells ([Figure 6E](#fig6){ref-type="fig"}). In HT22 cells as well as primary neurons, both CMS121 and J147 increased the phosphorylation of ACC1 at serine 79 ([Figure 6F,G](#fig6){ref-type="fig"}; Western blots shown in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Importantly, both CMS121 and J147 also increased phospho-ACC1 levels in the brains of the SAMP8 mice ([Figure 6H](#fig6){ref-type="fig"}). ACC1 phosphorylation was also elevated with aging, and this observation could be associated with a compensatory mechanism. In addition, inhibition of ACC1 by the compounds was accompanied by a decrease in free fatty acids in primary neurons ([Figure 6I](#fig6){ref-type="fig"}) as well as in the brains ([Figure 6J](#fig6){ref-type="fig"}) and plasma ([Figure 6K](#fig6){ref-type="fig"}) of old SAMP8 mice. Thus, inhibition of ACC1 can at least partially explain the increases in acetyl-CoA levels seen with both compounds ([Figure 6A and E](#fig6){ref-type="fig"}).

To test this hypothesis directly, ACC1 activity was blocked with the competitive inhibitor 5-(tetradecyloxy)−2-furoic acid (TOFA) or ACC1 expression was reduced with a specific siRNA. Both of these approaches significantly increased the levels of acetyl-CoA in the HT22 cells ([Figure 6L and N](#fig6){ref-type="fig"}). If acetyl-CoA is a key metabolite that contributes to the biological activity of CMS121 and J147, then inhibiting ACC1 activity or reducing its levels should phenocopy the compounds\' neuroprotective effects. [Figure 6M and O](#fig6){ref-type="fig"} show that both approaches were neuroprotective in HT22 cells exposed to glutamate. Similarly, both CMS121 and J147 as well as knocking down ACC1 expression protected HT22 cells from ferroptosis induced by RSL3 ([Figure 6P and Q](#fig6){ref-type="fig"}), a non-apoptotic form of regulated cell death that is similar to oxytosis, including mitochondrial dysfunction ([@bib27]; [@bib45]). In addition, consistent with the hypothesis that increases in acetyl CoA levels are protective, directly increasing acetyl-CoA levels by supplying cells with acetate, a cellular precursor of acetyl-CoA, was also protective ([Figure 6R](#fig6){ref-type="fig"}).

Finally, similar to what we found previously with J147 ([@bib21]), the inhibition of ACC1 by CMS121 was associated with AMPK activation ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). In addition, using cells that do not express AMPK, we found that the increases in acetyl-CoA levels and neuroprotection as a consequence of ACC1 inhibition are dependent on AMPK ([Figure 6---figure supplement 2A--C](#fig6s2){ref-type="fig"}).

Together, these data show that the preservation of brain mitochondrial gene expression and metabolism in the aging brain by both CMS121 and J147 is mediated by a shared mechanism involving the inhibition of ACC1 and increased levels of the central mitochondrial metabolite acetyl-CoA.

Discussion {#s3}
==========

Despite the observation that old age is the greatest risk factor for AD, few clinical approaches have focused on treating AD and other dementias by targeting detrimental age-related processes that are relevant to disease onset and development. In part, this is because we still lack a deep understanding of the aging brain. As such, our laboratory has developed a novel drug discovery program based upon cell-based screening assays that mimic multiple aspects of old age-associated neurodegeneration and AD pathology ([@bib37]) and has used a rapidly aging mouse model to study drug candidate effects in the context of aging ([@bib13]). This approach has led to the identification of CMS121 and J147, two potent neuroprotective small molecules. Because these compounds have different structures, but are effective in the same in vitro models of toxicities associated with the aging brain, we asked if they could be used to identify metabolic changes associated with age-related cognitive dysfunction, leading to the identification of novel therapeutic targets.

CMS121 and J147 were able to reduce age-related cognitive dysfunction, even when administered to SAMP8 mice at a late stage of their lives. In addition, CMS121 and J147 share a common mechanism of action that is associated with the maintenance of mitochondrial health in terms of transcriptional stability and metabolism. Mitochondrial dysfunction is one of the hallmarks of aging ([@bib29]), and an acceleration in this dysfunction may be responsible for the onset of AD pathology ([@bib43]; [@bib48]). Therefore, mitochondria represent an important therapeutic target for the treatment of AD ([@bib3]; [@bib34]).

Consistent with these observations, CMS121 and J147 reduced several molecular parameters of brain aging. PCA and drift analysis of the transcriptome showed that the two compounds significantly prevented changes in gene expression associated with aging. The level of suppression by CMS121 was particularly remarkable as evidenced in the correlation plots. Although not as strong, J147 also significantly prevented transcriptomic aging, which is in accordance with what we found in the SAMP8 mice treated from a young age (3 months old) with this drug candidate ([@bib13]).

The drift suppression was not as strong at the level of the brain metabolites as it was with gene expression. Instead, numerous metabolites that did not change with age were directly altered by the compounds. The effects of CMS121 and J147 on certain metabolic pathways and individual metabolites were very specific, namely the increase in acyl carnitines. Since acyl carnitines are direct substrates for fatty acid oxidation in mitochondria and a source of acetyl-CoA, they further support the conclusion that the compounds have a direct effect on mitochondrial metabolism in the brain. CMS121 and J147 also suppressed the metabolic drift in the plasma, indicating that the compounds may prevent the aging process at the systemic level as well.

Pathway analysis of the transcriptome identified genes that code for proteins that are part of the ETC and ATP synthase as being preferentially maintained at the younger level by the compounds. Mitochondria-related genes were also the top pathways affected by aging, indicating that mitochondrial dysfunction is part of the SAMP8 aging process. Because a decrease in mitochondrial DNA copy number was found with aging, the increased expression of gene transcripts associated with the ETC with aging is likely a compensatory response to a lack of adequate mitochondrial metabolism. The conclusion is supported by the observation that deficits in the respiratory chain and mitochondrial bioenergetics increase as a function of age ([@bib3]; [@bib29]), and by our data showing significant alterations in a number of TCA cycle metabolites in 13 months old SAMP8 mice.

Acetyl-CoA is a key metabolite that bridges glycolysis, fatty acid β-oxidation, fatty acid synthesis and the TCA cycle in the mitochondria. Its metabolism in the TCA cycle leads to the production of metabolites that are used in other metabolic pathways essential for the proper functioning of the cell, including the neurotransmitter acetylcholine which is reduced in forebrain neurons at early stages of the disease ([@bib33]). Acetyl-CoA is also used by histone acetyltransferases to acetylate histones and thus regulate memory formation ([@bib31]). In addition, the TCA cycle generates reducing potential that is used by the ETC. Therefore, our data have substantial implications for the therapeutic use of CMS121 and J147 in AD, given that deficits in mitochondrial metabolism are thought to play a key role in the cognitive dysfunction of AD patients.

Although acetyl-CoA can be derived from multiple sources, our data argue that the elevation of acetyl-CoA by the compounds is due to the inhibition of ACC1 via its phosphorylation by AMPK. This conclusion is based on the following observations: 1) both compounds cause ACC1 phosphorylation in vivo, primary neurons, HT22 cells and fibroblasts, and increase acetyl-CoA levels in all four models; 2) knockdown of ACC1 increases acetyl-CoA levels and provides neuroprotection; 3) chemical inhibition of ACC1 also increases acetyl-CoA levels and provides neuroprotection; and 4) absence of AMPK prevents the inhibition of ACC1, increases in acetyl-CoA levels and reduces the protection against oxytosis.

One of the few clinical approaches targeting mitochondrial metabolism that has been tested in the context of AD is the use of ketogenic diets. In animals, ketone bodies are mainly produced in the liver from fatty acid β-oxidation through acetyl-CoA and are then transported via blood to other tissues, such as the brain, where they are once again metabolized to generate acetyl-CoA. Administration of a variety of ketogenic diets has been shown to have some positive effects in both AD transgenic mice as well as human AD patients (reviewed in [@bib26]). Because CMS121 and J147 increase acetyl-CoA levels in the brains of animals and in vitro, our data suggest a therapeutic alternative to the ketogenic diet that leads to an improvement in mitochondrial health as well as an improvement in other parameters of aging.

Acetyl-CoA, along with several mitochondrial metabolites, has been directly implicated in the regulation of gene expression via the modification of chromatin (reviewed in [@bib25]). Histone acetylation requires acetyl-CoA that is synthesized in the cytoplasm and nucleus from acetate, citrate or pyruvate. These metabolites are intermediates of the TCA cycle and were all found to be altered with aging in SAMP8 mice. Other TCA metabolites, such as fumarate and succinate have been identified as inhibitors of Jumonji-C (JMJC) domain-containing histone demethylases (JHDMs) and TET demethylases, which rely on the TCA metabolite α-ketoglutarate as a co-substrate. The levels of all these metabolites were also altered in the brains of 13 months old SAMP8 mice. CMS121 and J147 decreased the levels of succinate and α-ketoglutarate. Therefore, it is not unexpected that alterations in mitochondrial metabolism in the 13 months old SAMP8 mice would be followed by changes at the level of gene expression.

It should be noted that, due to limitations in the amount of material, the transcriptomic analysis was carried out with brain hippocampus and that the metabolomic study was performed with brain cortex. Despite being from two different brain regions, the interpretation of the global effects of the compounds on these parameters with aging still hold valid. This is because network analysis using GAM identified acetyl-CoA as a central metabolite regulated by CMS121 and J147 in both cortex and hippocampus, and this finding was validated in primary neurons and HT22 cells. In addition, both transcriptomics and metabolomics also identified mitochondrial dysfunction as a feature of aging in SAMP8 mice in both tissues.

The link between brain acetyl-CoA metabolism and behavioral improvement caused by CMS121 and J147 may be the increased acetylation of H3K9, known to regulate the expression of genes involved in memory formation ([@bib31]). H3K9 acetylation was reduced in the brains of old SAMP8 mice as well as in the brains of APPswe/PSEN1dE9 transgenic AD mice. Both CMS121 and J147 increased acetylation at this site in the mouse brains as well as in primary cortical neurons. The ability of these compounds to prevent a large number of transcriptomic changes with aging might thus be a consequence of their direct effects on acetyl-CoA-mediated histone modifications.

The reason that the compounds share a common effect on metabolism is likely related to the fact that the same cell-based screening platform was used to identify both. In fact, some of these assays are characterized by mitochondrial dysfunction, such as the glutamate-directed oxytosis assay in HT22 cells ([@bib37]). We show that, despite engaging distinct initial molecular targets in the cell, the compounds activate mechanisms that overlap at the level of mitochondrial metabolism, leading to the same phenotypic outcome.

In conclusion, when administered at advanced stages of aging and cognitive dysfunction, two structurally distinct AD drug candidates preserve brain mitochondrial homeostasis during this period of life, making mice appear younger at the level of cognition, transcription and metabolism. The analysis of molecular pathways based upon data overlapping the action of CMS121 and J147 and respective mechanistic validation identified a unique neuroprotective mechanism that maintains acetyl-CoA levels in cell culture and animal models of aging and AD ([Figure 7](#fig7){ref-type="fig"}). Because mitochondrial dysfunction is a hallmark of both old age and AD, it follows that other therapies that target acetyl-CoA in the brain may preserve mitochondrial homeostasis and prevent the metabolic deficits in AD patients that occur with aging.

![Summary diagram.\
CMS121 and J147 preserve brain mitochondrial homeostasis with aging via a neuroprotective mechanism that regulates acetyl-CoA metabolism.](elife-47866-fig7){#fig7}

Materials and methods {#s4}
=====================

Study design {#s4-1}
------------

Twenty-three 9 months old female SAMP8 mice were fed with vehicle diet (LabDiet 5015, TestDiet, Richmond, IN), and twenty-two and twenty-two 9 months old female SAMP8 mice were fed with CMS121 and J147 diets, respectively (LabDiet 5015 + 400ppm CMS121, LabDiet 5015 + 200ppm J147, TestDiet). Diet treatment lasted for four months until mice reached 13 months of age. At 9 months of age, SAMP8 mice already present a strong phenotype ([@bib13]; [@bib11]; [@bib44]). The dose of J147 used was 200 ppm (\~10 mg/kg/day), which previously proved effective in mouse models ([@bib13]; [@bib36]; [@bib38]). For CMS121 we used 400 ppm (\~20 mg/kg/day), which was chosen based on its greater efficacy than its parent, fisetin, in in vitro assays and positive results with 500 ppm fisetin in the SAMP8 mice ([@bib14]). Eleven 9 months old female SAMP8 mice were used as the baseline control group.

The effect of the compounds was assessed in older SAMP8 mice after the four months of treatment and any age-related changes are defined by comparison to 9 months old SAMP8 mice. All mice were randomly assigned to experimental groups. The number of mice per group was determined based on previous experiments ([@bib13]; [@bib11]) and was sufficient to attain statistical power. Six SAMP8 mice fed with control diet, four SAMP8 mice fed with CMS121 diet and four SAMP8 mice fed with J147 diet died throughout the course of this study. Behavioral testing was carried out one month prior to sacrifice and collection of biological material. Data were analyzed by blinded researchers when appropriate.

SAMP8 mice {#s4-2}
----------

The SAMP8 line, a naturally occurring mouse line that was developed based on its phenotype of accelerated aging, was acquired from Harlan Laboratories (U.K.). Mouse body weights were measured regularly and no significant differences were found between the groups ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). All experiments were performed in accordance with the US Public Health Service Guide for Care and Use of Laboratory Animals and protocols approved by the IACUC at the Salk Institute.

Tissue preparation {#s4-3}
------------------

Mice were anesthetized and their blood collected by cardiac puncture. After perfusing with PBS, their brains were removed and dissected to collect cortex and hippocampus. Tissue was prepared for Western blotting, RNA extraction and metabolomic analysis.

Large-scale metabolome analysis {#s4-4}
-------------------------------

Metabolite measurement and analysis were conducted at Metabolon as previously described ([@bib13]).

Measurement of acetyl-CoA {#s4-5}
-------------------------

Acetyl-CoA levels were determined in protein-free lysates of primary neurons or HT22 cells treated as indicated in the figure legends using a kit from Sigma (MAK039) according to the manufacturer\'s instructions. The levels were normalized to the protein in the solubilized pellet using the BCA assay.

Supplemental materials and methods {#s4-6}
----------------------------------

### Cell lines {#s4-6-1}

Mouse hippocampal HT22 cells, generated in our laboratory, were propagated as previously described ([@bib17]). AMPK knockout (K.O.) mouse embryonic fibroblasts were a generous gift from Ruben Shaw (Salk Institute). The lack of AMPK expression can be verified by Western blotting ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). To prevent cell misidentification, large batches of each cell line were frozen that are regularly thawed to avoid using the wrong cell line. Cell lines are routinely tested for mycoplasma and no contamination has been found.

### Primary neurons {#s4-6-2}

Primary cortical neurons were prepared from day 17 rat embryos and used at 7 days in vitro (7 DIV) ([@bib42]).

### APPswe/PSEN1dE9 transgenic AD mice {#s4-6-3}

Samples from line 85 APPswe/PSEN1dE9 transgenic AD mouse mice and respective wild type (Wt) mice treated with J147 in a reversal experimental paradigm were obtained from our previous study ([@bib36]). In another independent study, 10 months old male Wt and APPswe/PSEN1dE9 mice were fed with vehicle diet (LabDiet 5015, TestDiet, Richmond, IN) or CMS121 diet (LabDiet 5015 + 400ppm CMS121) for three months and brain cortical tissue collected.

Behavioral assays {#s4-7}
-----------------

Elevated plus maze - The maze consisted of four arms (two open without walls and two enclosed by 15.25 cm high walls) 30 cm long and 5 cm wide in the shape of a plus. A video-tracking system (Noldus EthoVision) was used to automatically collect behavioral data. The software was installed on a PC computer with a digital video camera mounted overhead on the ceiling, which automatically detected and recorded when mice entered the open or closed arms of the maze and the time spent in each. Mice were habituated to the room 24 hr before testing and habituated to the maze for 1 min before testing by placing them in the center of the maze and blocking entry to the arms. Mice were then tested for a 5 min period and their behavior recorded. Disinhibition was measured by comparing the time spent on the open arms to time spent on the closed arms.

Barnes maze - The maze consisted of a flat circular surface (36' diameter) with 20 equally spaced holes (2' diameter) along the outer edge. One of the holes led to a dark hide box while the other 19 led to false boxes that were too small to be entered. The latency to enter the hide box was recorded. The test was conducted in three phases. Phase 1 (Training): A hide box was placed under one of the holes. Animals were placed into an opaque cylinder in the center of the maze for 30 s to promote spatial disorientation at the start of the test. After 30 s, the cylinder was removed and the animal explored the maze until it found and entered the hide box. The number of incorrect entries was scored. If the mouse failed to enter the box within 3 min, it was gently led into the box. The animal remained in the box for an additional 20 s before it was removed from the boxed and gently placed into the home cage. Training is repeated three times a day for four days. The location of the hide box remained the same during every trial but it was shifted between subjects to reduce the potential for unintended intra-maze cues. Phase 2 (Retention): This phase measures retention of spatial memory following a delay. After a two day break from training, each animal was re-tested for a one day, three-trial session using the same hide box location as before. Phase 3 (Reversal): This phase examines memory reversal. On the day following the retention phase, a new hide box location was established 180 degrees to the original location. The same method as before was used and trials were repeated three times a day over two consecutive days.

Western blotting {#s4-8}
----------------

Western blots were carried out as described previously ([@bib13]). The primary antibodies used were: HRP-conjugated rabbit anti-actin (\#5125, 1/20,000), acetyl-histone H3 (Lys9) (\#9649, 1/100000), phospho-ACC1 (\#3661, 1/2000), total ACC1 (\#4190, 1/1000), phospho-AMPK (\#2535, 1/1000) and total AMPK (\#2793, 1/1000), from Cell Signaling Technology; histone H3 (\#ab24834, 1/100000) from Abcam. Horseradish peroxidase-conjugated secondary antibodies (goat anti-rabbit, goat anti-mouse or rabbit anti-goat (BioRad) diluted 1/5000) were used.

Whole transcriptome analysis {#s4-9}
----------------------------

RNA was isolated from the hippocampus of SAMP8 mice or primary neurons using the RNeasy Plus Universal mini kit (Qiagen). RNA-Seq libraries were prepared using the Illumina TruSeq Stranded mRNA Sample Prep Kit according to the manufacturers instructions. Briefly, poly-A RNA was selected using poly dT-beads. mRNA was then fragmented and reverse transcribed. cDNA was end-repaired, adenylated and ligated with Illumina adapters with indexes. Adapter-ligated cDNA was then amplified. Libraries were pooled and sequenced single-end 50 base-pair (bp) on the Illumina HiSeq 2500 platform. Sequencing reads were mapped to the mm10 mouse genome or rn6 rat genome using the spliced aligner STAR (2.5.1b) with default parameters ([@bib18]). Reference mm10 mouse and rn6 rat genome was downloaded from UCSC. Only uniquely aligned reads were considered for downstream analysis. Expression values were quantified using Homer (4.9.1, [@bib22]) by counting reads mapped across all gene exons of RefSeq genes and mitochondrial encoded genes. The differential expression (DE) analysis was performed by edgeR (v3.16.1, [@bib30]). Briefly, genes with counts per million greater than one for at least half of the samples were normalized by the default 'TMM' method. The dispersion was estimated by the 'estimateGLMTagwiseDisp' function. Genes with a false discovery rate (FDR) \< 0.05 and an absolute log2 fold-change \>0.3 (about 1.23 fold-change) were identified as significantly differentially expressed. The data discussed in this publication have been deposited in NCBI\'s Gene Expression Omnibus ([@bib19]) and are accessible through GEO Series accession number GSE101112 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101112>).

Transcriptome/metabolome drift analysis {#s4-10}
---------------------------------------

Transcriptional drift analysis was performed as previously described ([@bib39]) with the exception that we removed expressed genes below the 20th percentile. We further normalized all samples setting the overall mean transcriptional drift to 0 to avoid differences in sample counts that affect drift variance across samples. Metabolomic drift variance was calculated by first determining the metabolomics drift (md) of each individual metabolite (md = log(old/young). The metabolomics drift variance is then determined by calculating the variance of md across the entire metabolome or subgroups of the metabolome.

Mitochondrial DNA copy number {#s4-11}
-----------------------------

Mitochondrial DNA copy number was determined in the hippocampus of SAMP8 mice using the kit from Detroit R and D, Inc (MCN 3) according to the manufacturer\'s instructions.

Bioinformatics and statistics {#s4-12}
-----------------------------

R package 'gplots' ([@bib46]) was used to generate the heatmaps and MSEAs. For the RNA and metabolic heatmaps, all values were mean-centered and divided by the SD of each variable (scaled Z-score). The heatmap of RNA-Seq was z-scaled log2(FPKM+5) for [Figure 3E](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"} and log2 fold-change for [Figure 3C and D](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}. Hierarchical clustering of RNA expression was performed using Euclidean distances and the Ward2 algorithm. K-means clustering of RNA expression was performed using Euclidean distances on z-scaled log2(FPKM+5) of 20077 expressed genes (at least one sample had greater than 0 FPKM). The total number of 20077 expressed genes were used as background for the DAVID pathway analysis for k1 cluster. MSEAs were generated according to HMDB and the 'Pathway-associated metabolic sets'. Only top pathways are indicated.

PCA of the transcriptome data was performed on the log2(FPKM+5) values of the top 10% most expressed genes (cutoff: RowSums(log2(FPKM+5))\>=110.41; 2458 genes selected) by the R base function 'prcomp' with data mean centered. Metabolome data was imputed to replace the missing value by the minimal value observed across all samples and transformed by the function 'glog' from the R package 'FitAR' (W. Huber, A. von Heydebreck, H. Sultmann, A. Poustka, and M. Vingron. Variance stablization applied to microarray data calibration and to quantification of differential expression. Bioinformatics, 18: S96-S10 2002) before PCA analysis. The ellipses showed the 70% confidence interval of a multivariate normal-distribution of sample groups estimated by PC1 and PC2 data.

Pathway enrichment test of the transcriptome data was analyzed by DAVID Bioinformatics Resources v6.8 ([@bib23] and [@bib24]). The total number of expressed genes of each individual pair-wise comparisons was used as background for the enrichment test.

Pathway enrichment analysis on metabolic pathways was conducted using the MetaboLync platform (Metabolon). Enrichment scores = (number of significant metabolites in pathway/total number of detected metabolites in pathway)/(total number of significant metabolites/total number of detected metabolites).

The metabolic network was reconstructed by GAM ([@bib40]) with input of the metabolome and/or the transcriptome dataset(s) and visualized by Cytoscape ([@bib41]).

Random Sampling: The dataset that contained the test statistics (p-value and fold-change) between 13 months+CMS121 and 13 months was used for the random sampling experiment. The Gene IDs and the Compound IDs were randomly shuffled 10 times (sampling without replacement) followed by the network analysis using the same parameters and cutoffs. The probability of observing acetyl-CoA in the resulted network was calculated as pnull. Random sampling p=pnull\^na\*(1-pnull)\^nb (na = number of experiments that identified acetyl-CoA in the network; nb = number of experiments that did not identify acetyl-CoA in the network). In this experiment, pnull = 0.1 and random sampling p=0.01. For the rat primary neuron transcriptome data, random sampling was performed using the same method with data generated from the comparison between CMS121 and control.

GraphPad Prism six was used for statistical analysis and exact *P* values are indicated (for p\<0.050).
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

In this paper the authors characterized two neuroprotective compounds, CMS121 and J147. Although these compounds target different upstream pathways, they are capable of preventing age-associated cognitive decline and metabolic changes in the mouse model. Using transcriptomics and metabolomics, the authors identified that the target pathways converge on the TCA cycle, and acetyl-CoA specifically, demonstrating its causative role in neuroprotection. The study not only enhances the translational value of the two compounds but also provides deeper understanding of processes that are effectively modulated in the course of drug administration. This study is also relevant for the broad audience, because it brings an important step in understanding of age-related pathologies, and provides a new concept to develop prevention strategies and cures.

**Decision letter after peer review:**

Thank you for submitting your article \"Elevating acetyl-CoA levels reduces aspects of brain aging\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Huda Zoghbi as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Lee-way Jin (Reviewer \#1); Martin Denzel (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The reviewers find the data valuable and interesting. However, they raised several points that must be addressed in the revised version. As you will see from the reviewers detailed comments appended below, the work requires a number of substantial revisions addressing the concerns. The number of them are to be addressed by additional justifications, explanations or toning down the interpretations. Specifically, the reviewers require to explain and justify an inconsistent experimental design, including the thorough analyses of statistical significance. The reviewers also agree that the manuscript should be experimentally enriched addressing the role of AMPK in mediating these effects. These additional experiments should be performed as thoroughly as possible given the time frame for revisions, i.e. focusing on most important effects and using cultured rat cortical neurons.

Essential revisions:

The data are complex; the readers will benefit from a diagram illustrating key pathways affected by senescence and by CMS121 and J147. Also, the authors state that \"the coordinated responses at the gene expression level with aging represent a compensatory mechanism that is linked to dysregulation at the metabolic level\". However, the authors only present correlational data and no evidence for this compensatory mechanism.

The description/explanation of the numbers and sexes of mice used is confusing:

1\) The authors used only female SAMP8 mice because \"women are at a higher risk than men of developing AD\". However, this is not exactly a study on AD. On the other hand, when it came to AD mice, only male APPswe/PSEN1dE9 mice were used.

2\) \"Eleven 9 months old male SAMP8 mice were used as the baseline control group.\" It is not clear how male \"baseline\" mice were used (in which experiments) and how their values were compared to female baseline.

3\) The Materials and methods indicates 4 mice per treatment group; however, it is indicated in Figure 1, n=5-6/group, and in Figure 2, n=11-18/group. Please clarify. A group number of 4 for behavioral tests is not likely feasible.

4\) Subsection "Increases in acetyl-CoA levels are neuroprotective and are associated with inhibition of ACC1 by CMS121 and J147": there is no Figure 1I, 1J and 1K.

5\) Materials and methods: \"Because the SAMP8 mice are an inbred strain, the effect of the compounds was only assessed in older SAMP8 mice after the four months of treatment.\" Please explain.

6\) Subsection "CMS121 and J147 enhance acetyl-CoA levels and histone acetylation in neurons": \"acetylation of H3K9 (in APPswe/PSEN1dE9 mice) was increased by the compounds\". However, the data and figure legend are confusing. First, comparing Figure 6---figure supplement 1 (D and E) and (F and G) -- the Ac-H3K9 level of Tg-AD animals in the latter is much smaller than the former (comparing the green bars), even they appears to be from similar animals. Second, in the legend to Figure 6---figure supplement 1, it is described that tissue in D and E was from 18 months and tissue in F and G was from 23 months. Why was that?

The transcriptome was done in the hippocampus while the metabolome was analysed in the cortex. This and how it affects the analysis of the data need to be explained.

The SAMP8 model needs to be interpreted more carefully regarding normal WT aging. In this context, it would be helpful to compare SAMP8 aging data with published data from WT mice during aging. This would solidify the model. Further, I wonder to what extent the changes in SAMP8 are representative for changes in AD?

The Western blots in Figure 6 show only minor changes. For example, the blot in Figure 6---figure supplement 1 A does not support the change documented in Figure 6C regarding Ac-H3K9. In Figure 6H, pACC1 levels go up with age, while compounds change the signal in the same direction. Thus, these data need to be interpreted more carefully.

The authors have previously identified ATP synthase as a target of J147, with downstream AMPK activation. Is this effect on ATP synthase responsible for the observed effects on the ETC, ACC1 and acetylation? This would be a plausible explanation but is only mentioned in the Introduction. It is therefore essential to experimentally test the role of AMPK in this context. Are the changes caused by the compounds regarding TCA metabolite levels, ACC1 phosphorylation, H3K9 acetylation, and neuroprotection caused by increased AMPK activity?

A color code label is missing for Figure 3 G and H.

The authors state in Figure 3A and B that the majority of the changed genes are the same. It would be great to back this up by showing the overlap. What proportion of these genes are the upregulated fraction?

The text does not properly explain the neurotoxicity assay in Figure 6E.

Generally, the text should follow the order of the figures. In the manuscript, the reader has to jump between sections, making it harder to read. The results in Figures 4, 5, and 6, for example, are presented in a way that is a bit confusing. It would be better to arrange the figures to the order of the text or change the text so that it is not necessary to jump between the figures.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for submitting your article \"Elevating acetyl-CoA levels reduces aspects of brain aging\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Huda Zoghbi as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The reviewers were largely satisfied with the revisions they have requested. However, there is one remaining issue that needs to be addressed experimentally. The authors show that the compounds appear to act through ACC1 inhibition. Inhibition of ACC1 has two consequences: elevated acetyl-CoA and the reduced flux in downstream metabolism. Which of the two effects of ACC1 inhibition is responsible for the observed phenotype should be clarified by experimentally elevating Acetyl-CoA levels by acetate supplementation.
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Author response

> Essential revisions:
>
> The data are complex; the readers will benefit from a diagram illustrating key pathways affected by senescence and by CMS121 and J147.

A diagram summarizing the findings has been added as Figure 7.

> Also, the authors state that \"the coordinated responses at the gene expression level with aging represent a compensatory mechanism that is linked to dysregulation at the metabolic level\". However, the authors only present correlational data and no evidence for this compensatory mechanism.

The sentence has been modified to \"We next tested the hypothesis that the coordinated responses at the gene expression level with aging are associated with dysregulation at the metabolic level\".

> The description/explanation of the numbers and sexes of mice used is confusing:
>
> 1\) The authors used only female SAMP8 mice because \"women are at a higher risk than men of developing AD\". However, this is not exactly a study on AD. On the other hand, when it came to AD mice, only male APPswe/PSEN1dE9 mice were used.

In order to keep the study affordable and viable, we focused on one gender only. In the past, we have used male mice from the APPswe/PSEN1dE9 strain. Recently, as we started working with the SAMP8 strain, we chose female mice, given that women are at a higher risk than men of developing AD. In order to avoid confusion, we have removed the sentence above from the manuscript.

> 2\) \"Eleven 9 months old male SAMP8 mice were used as the baseline control group.\" It is not clear how male \"baseline\" mice were used (in which experiments) and how their values were compared to female baseline.

This was a typo and has been corrected to \"female SAMP8 mice\".

> 3\) The Materials and methods indicates 4 mice per treatment group; however, it is indicated in Figure 1, n=5-6/group, and in Figure 2, n=11-18/group. Please clarify. A group number of 4 for behavioral tests is not likely feasible.

The number of mice in this sentence reflects the mice that died during the course of our study\"Six SAMP8 mice fed with control diet, four SAMP8 mice fed with CMS121 diet and four SAMP8 mice fed with J147 diet died throughout the course of this study\". The numbers stated in the figure legends are correct.

> 4\) Subsection "Increases in acetyl-CoA levels are neuroprotective and are associated with inhibition of ACC1 by CMS121 and J147": there is no Figure 1I, 1J and 1K.

This was a typo and has been amended. It should read Figure 6I, 6J and 6K.

> 5\) Materials and methods: \"Because the SAMP8 mice are an inbred strain, the effect of the compounds was only assessed in older SAMP8 mice after the four months of treatment.\" Please explain.

Because we are assessing the effects of our compounds on the aging phenotype, the control group was comprised of 9 months old SAMP8 mice, prior to compound treatment.This sentence has been clarified and now reads \"The effect of the compounds was assessed in older SAMP8 mice after the four months of treatment and any age-related changes are defined by comparison to 9 months old SAMP8 mice.\".

> 6\) Subsection "CMS121 and J147 enhance acetyl-CoA levels and histone acetylation in neurons": \"acetylation of H3K9 (in APPswe/PSEN1dE9 mice) was increased by the compounds\". However, the data and figure legend are confusing. First, comparing Figure 6---figure supplement 1 (D and E) and (F and G) -- the Ac-H3K9 level of Tg-AD animals in the latter is much smaller than the former (comparing the green bars), even they appears to be from similar animals. Second, in the legend to Figure 6---figure supplement 1, it is described that tissue in D and E was from 18 months and tissue in F and G was from 23 months. Why was that?

These tissues were generated as part of two separate studies with Tg-AD mice that we had carried out previously. The tissues were already available in our laboratory. Therefore, the differences observed in H3K9 acetylation between mice from the two independent studies might be explained by the age difference. This has been clarified in the Materials and methods and legend of Figure 6---figure supplement 1.

> The transcriptome was done in the hippocampus while the metabolome was analysed in the cortex. This and how it affects the analysis of the data need to be explained.

There was not enough tissue to carry out both the transciptomics and metabolomics with the same area of the brain. Based upon data for pathway identification, the global effects of the compounds on these parameters with aging still hold valid despite being from two different parts of the brain, both of which are affected in aging and AD. This is because network analysis using genes and metabolites (GAM) identified acetyl-CoA as a central metabolite regulated by CMS121 and J147 in both cortex and hippocampus, and this finding was further validated in primary neurons, HT22 cells and fibroblasts. In addition, both transcriptomics and metabolomics also identified mitochondrial dysfunction as a feature of aging in SAMP8 mice in both tissues. We have added this information to the Discussion.

> The SAMP8 model needs to be interpreted more carefully regarding normal WT aging. In this context, it would be helpful to compare SAMP8 aging data with published data from WT mice during aging. This would solidify the model. Further, I wonder to what extent the changes in SAMP8 are representative for changes in AD?

There are a large number of publications detailing how the phenotype developed by SAMP8 mice with aging is directly relevant to brain aging, and why they should be considered as a model of dementia and sporadic AD (Butterfield et al., 2005; Pallas et al., 2008; Takeda, 2009; Morley et al., 2012; Akiguchi et al., 2017). Some of the pathological traits developed by the SAMP8 mice with aging that are also found in AD include: progressive decline in brain function with early deterioration in learning and memory; increased oxidative stress; inflammation; vascular impairment; gliosis; Aβ accumulation and tau hyperphosphorylation (Takeda, 2009; Morley et al., 2012; Cheng et al., 2014). It is very difficult to compare changes at the molecular level between different strains of mice due to the genetic variability inherent to each strain. There is no ideal mouse model for AD at the moment, but the SAMP8 mice appear to be one of the best to study the overlap of aging and AD. This information and respective references were added and discussed more thoroughly in the revised text.

> The Western blots in Figure 6 show only minor changes. For example, the blot in S5A does not support the change documented in Figure 6C regarding Ac-H3K9. In Figure 6H, pACC1 levels go up with age, while compounds change the signal in the same direction. Thus, these data need to be interpreted more carefully.

The data presented in Figure 6C is a result of unbiased band quantification. It should be noted that values of H3K9 acetylation were normalized to total H3 protein, which may be visually misleading. We agree with the reviewers that the data should be interpreted carefully and that is what we tried to do. One possible explanation for the increases in ACC1 phosphorylation in SAMP8 mice with aging could be that this increase represents a compensatory mechanism. This information has now been discussed in the text.

> The authors have previously identified ATP synthase as a target of J147, with downstream AMPK activation. Is this effect on ATP synthase responsible for the observed effects on the ETC, ACC1 and acetylation? This would be a plausible explanation but is only mentioned in the Introduction.

In our previous study (Goldberg et al., 2017), we showed that decreasing ATP synthase activity activated AMPK and increased ACC1 phosphorylation. Because ATP synthase has only been identified as the target of J147 and not CMS121, it was not the focus of our study. However, we did carry out experiments to address the role of AMPK in the signaling pathway identified, and these new data were added to the revised text, as detailed next.

> It is therefore essential to experimentally test the role of AMPK in this context. Are the changes caused by the compounds regarding TCA metabolite levels, ACC1 phosphorylation, H3K9 acetylation, and neuroprotection caused by increased AMPK activity?

We have now tested the role of AMPK in the mode of action of CMS121 and J147. Using fibroblasts (obtained from Ruben Shaw at Salk Institute) that do not express AMPK (knock out) we show that, similar to what we had found with J147 (Goldberg et al., 2017), the absence of AMPK also reduces the protection against oxytosis by CMS121. In addition, we show that the absence of AMPK prevents the phosphorylation (inhibition) of ACC1 as well as the consequent increases in acetyl-CoA levels. These new data are described in the text and appended as Figure 6---figure supplement 2. Altogether, these results support our conclusion that ACC1 may be a novel target for AD therapy.

> A color code label is missing for Figure 3 G and H.

The label has been added to the figures.

> The authors state in Figure 3A and B that the majority of the changed genes are the same. It would be great to back this up by showing the overlap. What proportion of these genes are the upregulated fraction?

A diagram showing the overlap of genes was added to Figure 3B. In addition, this information was made clearer in the text, \"The top KEGG pathway targeted by both aging and CMS121 was oxidative phosphorylation (OP). \[...\] Surprisingly, the expression of all these genes went up between 9 and 13 months in the SAMP8 mice and this was prevented by CMS121 and J147 (Figure 3C).\". The figure legend was also altered accordingly.

> The text does not properly explain the neurotoxicity assay in Figure 6E.

This was made clearer in the text, \"The primary phenotypic screening model used in our laboratory to identify CMS121 and J147 (Chen et al., 2011; Chiruta et al., 2012) (Figure 6E) relies on the lethal induction of mitochondrial ROS in the mouse hippocampal neuronal cell line HT22 (Prior et al., 2014), a programmed cell death pathway called oxytosis with physiological features similar to those implicated in the nerve cell damage seen in aging and AD (Currais and Maher, 2013; Tan, Schubert, and Maher, 2001). Oxytosis can be triggered by glutamate which inhibits cystine uptake via system X~c~^-^, leading to depletion of intracellular glutathione (GSH), production of ROS and cell death (Tan et al., 2001)\".

> Generally, the text should follow the order of the figures. In the manuscript, the reader has to jump between sections, making it harder to read. The results in Figures 4, 5, and 6, for example, are presented in a way that is a bit confusing. It would be better to arrange the figures to the order of the text or change the text so that it is not necessary to jump between the figures.

The text in the Results section has been reorganized to match the order of the respective figures. Some graphs in Figure 6 have also been rearranged to follow their description in the text.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The reviewers were largely satisfied with the revisions they have requested. However, there is one remaining issue that needs to be addressed experimentally. The authors show that the compounds appear to act through ACC1 inhibition. Inhibition of ACC1 has two consequences: elevated Ac-CoA and the reduced flux in downstream metabolism. Which of the two effects of ACC1 inhibition is responsible for the observed phenotype should be clarified by experimentally elevating Acetyl-CoA levels by acetate supplementation.

As per your suggestion, we have now experimentally elevated acetyl-CoA levels by supplementing cells with acetate, a cellular precursor of acetyl-CoA (Pietrocola F., et al. Cell Metabolism, 2015). This was protective in our model, as shown in Figure 6R, supporting our overall conclusions. These new data have been added to the manuscript.
